Wait a second!
More handpicked essays just for you.
More handpicked essays just for you.
The role of business ethics in the corporate world
Role of business ethics in corporate governance
Business ethics in corporation
Don’t take our word for it - see why 10 million students trust us with their essay needs.
Recommended: The role of business ethics in the corporate world
An issue in the past year within a privately held company called Turing Pharmaceuticals brought up questions on whether the choice made by the company were ethical or unethical. An article by Steven Brachmann, published on September 24, 2015 gives us an overview of this. Overview: Pyrimethamine, a prescribed medicine for Toxoplasmosis which results from infection with a parasite found in cat feces and contaminated food, which is marketed under the brand name Daraprim was the main substance of this unethical issue. This whole issue started when Turing Pharmaceuticals decided to buy the rights to sell Daraprim from the hand of Impax Laboratories Inc. on August 10, 2015. Soon after obtaining the authority to sell Daraprim, Martin Shkreli, founder and CEO of Turing Pharmaceuticals, raised the price from $13.50 per pill to $750 per pill, by more than 5,000 percent. This choice of the company caused an outcry in the public. This greed made him one of public’s number one enemy. Impact on Society: …show more content…
When Shkreli pointed out that it was not profitable for the company to sell the drug at $13.50 a pill, it is clear that he had no intention in being socially responsible. Even though the Martin Shkreli claimed to the press that their plans were to “launch an educational effort to help raise awareness and improve diagnosis for patients with toxoplasmosis” (IPWatchdog.com) there were no later actions. By failing meet the legal, ethical, economic and voluntary responsibilities placed on this company by their stakeholders, Turing Pharmaceuticals failed to meet the commitment of corporate
Today, there are so many legal dilemmas dominating trial for the courts to make a sound legal decision on whose right in a complicated situation. Despite the outcome of the case, the disagreement usually has a profound effect on the healthcare organization, and the industry as a whole. Many cases are arguments centered around if the issue is a legal or moral principle. Regardless what the situation maybe, the final decision is left to the courts to differentiate between the legality issues at hand opposed to justifying a case based on moral rules. According to Pozgar (2012), an ethical dilemma arises in situations where a choice must be made between unpleasant alternative. It can occur whenever a choice involves giving up something good and suffering something bad, no matter what course of action is taken (p. 367). In this paper, I will discuss cases that arose in the healthcare industry that have been tried and brought to justice by the United States court system.
Deontology theory defines an ethical action as one that adheres to a set of rules and duties. PharmaCARE’s actions are unethical by way of this moral compass because the firm has failed to perform in accordance with one very important duty, the duty to safeguard human dignity and basic human rights. Paying $1 a day to its workers and not providing them with even the most basic of amenities is a gross violation of the firm’s obligation to safeguard human rights, which in itself is a morally required behavior and applicable almost universally. PharmaCARE is not treating the Colberians like the treat their executives, nor are they treating the community there as they treat the communities in the
It is the profits rather than the need of the world that drives the market, as Cahill points out. She laments that while in the 1960-1970 's theologic bioethicists influenced the field of bioethics, nowadays the ethical discourse involving Christian narrative gets" thinner and thinner," shifting away toward more secular and liberal views. As theologians are welcomed to partake in the ethical debates, their voices and opinions are rarely considered in policy making. Such situation causes the current trend amongst health care institutions,medical-surgical companies, and research labs, to focus on financial gain rather than ways to deliver health care to those who needed it the most. It is the consumers with the most "buying power" that have at their disposal the latest medical treatment, equipment, technologies, and medications while millions around the world lack the most basics of needs, such as clean water, food, shelter, education as well as the basic health care. Cahill fears that medical companies seeking profits will neglect or stop altogether to produce medications that are bringing low profits. Medications that are necessary to treat prevalent in the third- world countries or if you prefer the developing countries diseases, such as Dysentery, Cholera, Malaria, Rabies, Typhoid Fever, Yellow Fever, even warms, to name a
.... Arkansas has one of the highest numbers of STLs in the United States. In an effort to recoup the costs of dealing with the meth epidemic, twenty counties in Arkansas filed a suit in a federal district court against Pfizer, Inc., and other companies that make or distribute cold and allergy medications. What is the defendants’ ethical responsibility in this case, and to whom do they owe it? Why? [Ashley County, Arkansas v. Pfizer, Inc., 552 F.3d 659 (8th Cir.2009)]
...pecially with the use of DTC advertising, to such a wide range of afflictions greatly increased their consumer base, but one of them proved to be deadly. In 1999, four years after Lilly sent study results to the U.S. Food and Drug Administration showing Zyprexa didn’t alleviate dementia symptoms in older patients, it began marketing the drug to those very people, according to documents unsealed in insurer suits against the company for overpayment.(Applbaum, 248). Soon after it began to be used in those suffering from dementia, there were studies produces that showed an increase in death rate among elderly patients taking Zyprexa. In January of 2009, Eli Lilly and Company, who produced the drug, ended up settling the lawsuit and agreed to pay $1.415 billion which was one of the biggest corporate settlements in the history of pharmaceutical companies (Applbaum, 237).
Many businesses that achieve great success become greedy and want more. Pharmaceutical companies, such as Turing, have been overpricing life-saving
Yu, Winnie and Joel Hay. 1999. “Drug Patents and Prices: Can we Achieve Better Outcomes?” Measuring the Prices of Medical Treatments. Pages 27-28.
Main Issue In 2000, Rich Kender, Vice President of Financial Evaluation and Analysis at Merck & Company was discussing the opportunity of investing in licensing, manufacturing and marketing of Davanrik, a drug originally developed to treat depression by LAB Pharmaceuticals. LAB proposed to sell the rights of all the future profits made from the successful launch of Davanrik at the cost of an initial fee, royalty payments and additional payments as the drug completed each stage of the approval process. Merck & Company's organizational goal is to constantly refresh its drug development portfolio and reach as many customers as possible during the patented period. So there was not only the potential of financial gain or quantitative aspect of the offer, but also the qualitative value which will be added by getting better positioning in the risky pharmaceutical industry.
3Walker, Hugh: Market Power and Price levels in the Ethical Drug Industry; Indiana University Press, 1971, P 25.
Martinez, Barbara “Firms Paid to Trim Drug Costs Also Toil for Drug Makers” The Wall Street
For instance, 20 largest United States (“U.S.”) based companies are now conducting one third of their clinical trials outside the U.S. According to a report from the inspector general of Department of Health and Human Services (“DHHS”) the number of clinical trials conducted at foreign sites has increased to 6,485 in 2008 from 271 trials in 1990. This trend suggests that the outsourcing of clinical trials has become one of important aspects of business fostering development of safe and effective drugs and devices that are interest of through out the world but at same time raising many ethical and scientific concerns.
In recent years’ health reform has been a driving force in the United States political system. If you watch the news, you will understand how citizens, the government, or the economy are or might be affected by some sort of change in medical regulation. One of these hot topic issues is the cost of prescription drugs. Every major drug market besides the United States regulates the price of drugs in some way (Abbott and Vernon). By the United States not doing so, many believe it opens consumers up to being exploited by large pharmaceutical companies.
Most hated man in America, Martin Shkreli. Thirty three year old man received this title after a 5,000 percent increase price of Daraprim from 13.50 dollars a pill to 750 dollars. Daraprium is an antiparasitic to prevent infection such as AIDS, malaria, etc. After being streamed in the media, people started posting negative comments about Martin Shkreli. People questioned his experience in drug or disease research. According to Lee, Martin Shkreli had no real experience with disease research all he was good at was reading and memorizing medical journals and textbooks. Not having knowledge of the disease, it demonstrates that he does not care about his customers. Successful entrepreneurs like Martin Shkreli, money is what is considered important
The rights to protect the public were brutal to public trust provided that the leaders of Merck and the FDA abused their powers to gain social control by deliberately marketing a deadly drug (Mumford, Zaccaro, Harding, Jacobs, & Fleishman, 2000; Smith, 2007). The leaders involved that of FDA commissioners received data from Merck regarding Rofecoxib also known as Vioxx about the health risks, yet failed to release
"Pharma Firm Lundbeck Wins Ethical Award for Stopping Use of Drugs in Executions." Reprieve. March 29, 2012. http://www.reprieve.org.uk/press/2012_03_29_lundbeck_ethical_award/.